ODAC votes to keep Keytru­da and Tecen­triq ac­cel­er­at­ed ap­provals in blad­der can­cer

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee is con­tin­u­ing to find it dif­fi­cult to say no to can­cer pa­tients, es­pe­cial­ly as blad­der can­cer pa­tients af­fect­ed by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER